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2 UNDERSTANDING MODERN VACCINESVaccines have dramatically improved human health. The steady
decline in deaths in children under 5 years of age is attributable to
the increasing availability of vaccines in the developing world.
A growing knowledge of immunology has increasingly inﬂuenced
vaccine design in the past century, leading to the production of
new types of vaccines (whole cell, live or inactivated, subunit,
recombinant proteins etc) with associated advantages and
challenges. In addition, public health priorities have evolved over
time. The ﬁrst vaccines were developed against diseases with high
morbidity and mortality rates, such as smallpox, diphtheria and
tetanus. In addition, ‘battleﬁeld diseases’ e particularly in the era
of trench warfare e including typhoid fever, plague and cholera,
drove the development of early vaccines.
More recently, the drivers for vaccine development have changed,
reﬂecting changes in global society. Although highly pathogenic
infectious diseases remain the principal targets for effective
vaccination, assessments of beneﬁt versus risk and consideration
of health economics are now an obligatory part of the development
process. Better understanding of immunology and pathogenesis of
the targeted diseases facilitates identiﬁcation of the type and quality
of immune responses that are desirable for each new prophylactic
or therapeutic vaccine.
Smallpox and polio e two
success stories
In December 1979, the World Health Organization (WHO)
announced the eradication of smallpox following successful
vaccination campaigns throughout the previous two centuries.
Another disease presently close to eradication is polio (Figure 1.1).
The WHO declared that the Americas were polio-free in 1994,
followed by the Western Paciﬁc region in 2000 and the European
region in 2002. In the past 20 years, polio cases have decreased
from an estimated 350,000 annual cases to 1640 cases in 23
countries in 2009, the majority of which (69%) occurred in Nigeria
and India.
Figure 1.1 Hospitalised victims during the polio outbreak of the 1950s. During the polio epidemics of the 1950s, entire wards were ﬁlled
with people obliged to rely on an ‘iron lung’ due to paralysis of the respiratory muscles. Some patients would remain this way for the rest of
their lives.
March of Dimes Foundation.
VACCINE EVOLUTION 3Vaccination e how and where did
it start?
In the ancient world, it was common knowledge that a person was
rarely infected twice with the same disease and the term ‘immunity’
was ﬁrst used in reference to plague in the 14th century.
Figure 1.2 Child with smallpox. The last naturally occurring
case of smallpox was reported in 1977 in Somalia.
Centers for Disease Control and Prevention.
4 UNDERSTANDING MODERN VACCINESInoculation is a long-established practice that protected humans
and animals from contagious diseases e it has been practised in
various Asian and African countries for centuries. Madhava
Nidana, a classical text of traditional Ayurveda, is one of the ﬁrst
written reports of attempts to inoculate and dates back to 7th
century India.
The development of natural sciences and experimental methods
during the 18th century led to the systematic use of inoculation to
ﬁght one of the most signiﬁcant threats of this era, smallpox, also
known as the ‘speckled monster’ (Figure 1.2).VARIOLATION AND INOCULATION
Inoculation, or variolation in the case of smallpox, involved
subcutaneous administration of liquid taken from a pustule of
a person showing mild clinical symptoms, and represented the
precursor to live pathogen vaccines. In Europe, the new methods of
variolation quickly became known amongst physicians. Since there
was an increasing demand for protection against smallpox,
physicians soon began the variolation procedure on a large scale.
However, variolation was not without its attendant risks; there were
concerns that recipients might spread smallpox to others, or
develop a systemic infection. Approximately 2e3% of variolated
persons died from the disease, or suffered from other diseases
such as tuberculosis (TB) or syphilis transmitted by the human
to human inoculation procedure. Despite the risks, mortality
associated with variolation was 10 times lower than that associated
with naturally occurring smallpox. During a smallpox epidemic in
Boston in 1721, half of the 12,000 population was infected and
mortality was 14%; in comparison, mortality in variolated individuals
was only 2% (Blake, 1959).VACCINATION
The use of cowpox as a vaccine for smallpox is generally seen as
a remarkable advance over variolation. Variolation used human
material, including serous matter from pustules and scabs taken
Figure 1.3 Lady Montague. In the early 18th century, variolation was introduced to
England by Lady Mary Wortley Montague, following her experience of the procedure
in Turkey.
Zenodot Verlagsgesellschaft mbH and licensed under the GNU Free
Documentation License.
VACCINE EVOLUTION 5from a patient with a mild case of the disease, and generally
conferred strong, long-lasting immunity. The ﬁrst smallpox vaccine
for general use was introduced by Edward Jenner in 1796 (there
Introduction of variolation in
Europe and North America
Lady Montague (Figure 1.3), who had
survived infection with smallpox (variola)
herself,wasso impressedwith themethod
of variolation used in the Ottoman court
(which involved cutaneous inoculation of
smallpox pus) that she ordered the
embassy surgeon, Charles Maitland, to
inoculate her 5-year-old son. Upon their
return to London in 1721, Lady Montague
instructed Maitland to inoculate her
4-year-old daughter in the presence of
physicians of the royal court. The results
convinced the Princess of Wales to
inoculate her own children in the same
way. As a result, the procedure was
generally accepted and became quite
popular. Simultaneously, variolation was
alsoﬁrst practised in 1721 inBostonusing
knowledge gained from an African slave,
Onesimus, who was inoculated as a child
in Africa.
6 UNDERSTANDING MODERN VACCINESwas a private inoculation of his family by a farmer named Jesty
in 1774 prior to Jenner’s inoculation) based on anecdotal
observations that milkmaids infected by cowpox, a benign
infection for humans, were subsequently immune to smallpox. By
deliberately inoculating people with small doses of cowpox from
pustules on the udders of infected cattle, Jenner demonstrated
that protection against smallpox could be achieved (Figure 1.4).
The ﬁrst person he inoculated was James Phipps on the 14 May
1796; he later challenged him with fresh smallpox pustular
material. Through a form of cross-protective immunity, cowpox
vaccination provided humans with satisfactory protection,
although it was probably less durable than that produced by
inoculation with smallpox. Jenner called this preventive measure
‘vaccination’ (vaccinia, from Latin vacca ¼ cow) and his practice
of inoculation against smallpox using cowpox became widely
accepted by the end of the 18th century. The Royal Jennerian Society
was founded in London in 1803, and in a period of 18 months
approximately 12,000 individuals were vaccinated.
Cowpox vaccination was made more efﬁcient by performing
human arm-to-arm transmission of infectious cowpox ﬂuid,
which greatly increased the capacity for providing vaccinations
to larger numbers of people as it did not rely on the sporadic
outbreaks of cowpox in cattle. However, this method was
not without problems, including an apparent decline in the
potency of the vaccine which necessitated revaccination in
order to maintain immunity and the concomitant transmission of
other infections.
During the latter half of the 19th century, cows and calves were
again used as a lymphatic ﬂuid source to re-obtain a potent
cowpox-based vaccine. Following the observation that the quality of
the isolated ﬂuid rapidly declined, Robert Koch recommended that
glycerine be added to kill contaminating bacteria. This preservation
method soon became standard practice.
Many inoculation techniques were used for smallpox vaccination
over the years. When improvements in vaccine potency resulted
Figure 1.4 Smallpox inoculation procedure in the 18th century. In 1796, Edward Jenner, a general practitioner and surgeon, inoculated 8-year-old
James Phipps with material from cowpox blisters of a milkmaid. The boy developed a mild fever and was subsequently immune to smallpox.
Collection of the University of Michigan Health System, gift of Pﬁzer Inc. UMHS.23.
VACCINE EVOLUTION 7in excessively severe reactions with the inoculation techniques
practised so far, multiple puncture methods, eg using a bifurcated
(two-pronged) needle (Figure 1.5, panel A) or scariﬁcation
Figure 1.5 Multiple puncture needles used for smallpox
inoculation. Needles used to prick the skin during
inoculation with smallpox. A: bifurcated needle;
B: scariﬁcation instrument.
Centers for Disease Control and Prevention (A). Courtesy of
Professor Myron Levin (B).
The ﬁrst vaccination
programme in history
The New World was ravaged by smallpox
for several centuries after the Spanish
conquest. In 1804, 6 years after Jenner’s
publication, the ﬁrst and little known
effort to eradicate smallpox for good was
commissioned by Charles IV of Spain, in
response to a large outbreak of smallpox
in the Spanish colonies. Known as the
Royal Philanthropic Expedition, King
Charles IV appointed Francisco Xavier de
Balmis to take Jenner’s vaccine to the
Spanish colonies, the Philippines and
China. During the journey from Spain to
the New World, the vaccine was kept
viable by passing it from arm-to-arm in
orphaned children, who were brought
along expressly for that purpose.
8 UNDERSTANDING MODERN VACCINESinstrument (Figure 1.5, panel B), were implemented. However, the
simple cut or scratch technique also remained popular throughout
the smallpox vaccination period.
THE GERM THEORY OF DISEASE
Until the late 19th century, diseases were commonly believed to be
caused by an invisible agent, a miasma, and were ‘spontaneously
generated’ in response to ‘bad air’ and other environmental triggers.
Infectious illnesses were also believed to be caused by imbalances
in the body. While Jenner had no knowledge of microorganisms and
viruses, progress in microbiology from the late 19th century onwards
developed into the modern concept of communicable diseases.
Hence, further advances in vaccinology were gained from an
understanding of what caused infectious diseases e the science of
aetiology and hostepathogen interactions.
Through the pioneering research of Louis Pasteur and Robert
Koch, who established that microorganisms were the cause of
infectious diseases, the science of immunology was founded.
Pasteur disproved the spontaneous generation theory of
microbes, and his studies of the metabolism of microorganisms
led to the discovery of ways in which microbes could be
transformed so as to produce vaccines and other new ways to
prevent and treat infection. Koch demonstrated that infectious
agents transmit diseases and his four postulates established
a speciﬁc agent as the cause of a disease. Today, Koch’s
postulates (Table 1.1) are still sound principles for determining
causality. An overview of discovery of some speciﬁc pathogens
and the availability of vaccines for diseases caused by these
pathogens is shown in Figure 1.6. It can be seen from this ﬁgure
that in the case of smallpox, a successful vaccine could
be developed without knowledge of the actual nature of the
causative agent.
ATTENUATED AND INACTIVATED PATHOGENS
Pathogen attenuation was used to develop vaccines in Pasteur’s
laboratory by Émile Roux in the late 1870s, when he suspended
TABLE 1.1. KOCH’S POSTULATES
1. The microorganism must be identiﬁed in any stage of disease in the infected host.
2. The microorganism must be isolated from the host and grown in pure culture outside the host.
3. Infection of healthy susceptible hosts with the cultured microorganism must result in the same symptoms of the disease.
4. The microorganism must be re-isolated from the experimentally infected host and shown to be identical with the original isolate.
Adapted from Koch (1884).
Figure 1.6 Pathogen isolation and vaccines. Depending on availability of appropriate technology, there may be considerable variations in time
between pathogen identiﬁcation ( ) and development of a vaccine ( ). In the case of smallpox, a vaccine was available long before viruses as
causing agents were known. The rabies vaccine was also developed before knowing the causative agent. A pathogen, like varicella zoster
virus, may cause different diseases (varicella and zoster) for which separate vaccines have been developed.
HPV, human papillomavirus; Hib, Haemophilus inﬂuenzae type b.
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Attenuation of vaccines
An attenuated vaccine contains an
infectious, but less virulent, pathogen that
inducesamild formofdisease.Attenuated
vaccines typically stimulate strong,
durable antibody- and cell-mediated
immune responses. An attenuated
vaccine has the disadvantage of
potentially being associated with a small
risk of vaccine-related disease, especially
in individuals with underlying impairment
of immunefunction.Furthermore, forsome
attenuated vaccines, there are safety
concerns about the potential for reversion
from the attenuated form back to a
virulent one.
How attenuation of pathogens
was discovered
Pasteur developed methods for the
attenuation of pathogens thanks to the
involuntary negligence of one of his
co-workers in his laboratory, who left an
avian cholera culture (Pasteurella
multocida) exposed to air for an extended
period of time prior to inoculation
experiments in chickens. This resulted in
a revolutionary discovery, as the cultured
microbes lost their ability to induce
disease in chickens, but left these
chickens immune to a virulent culture of
avian cholera. Pasteur concluded that
weakened microbes could provide, in
general, immunity to infectious diseases.
10 UNDERSTANDING MODERN VACCINESthe spinal cord of a rabbit infected with rabies in a ﬂask in
a warm dry atmosphere to achieve slow desiccation of the
infectious material. This produced a weakened substance
for inoculation.This practice rendered the microorganisms less pathogenic but
still immunogenic. Pasteur and his team then succeeded in
producing attenuated microorganisms of different strengths by
varying the desiccation time. On 6 July 1885, a 9-year-old boy,
Joseph Meister, became the ﬁrst human to be successfully
vaccinated with a live, attenuated vaccine against rabies. This
method was not widely accepted however, as a few fatal cases of
rabies in those vaccinated were attributed to the vaccine and
viewed as ‘medical murders’, in spite of the fact that hundreds
of people exposed to rabies had been saved from death as a result
of vaccination.
Almost in parallel to attenuated pathogens, researchers started
working on inactivated pathogens. These were initially developed for
veterinary applications, based on the observation that inactivated
pathogens maintained the ability to induce protection. The ﬁrst
inactivated vaccines developed for human use were against typhoid,
cholera and plague.
There are, however, some disadvantages associated with
inactivated whole pathogen vaccines. Multiple doses are generally
needed to provide sufﬁcient stimulation of the immune system and
booster doses may be needed to induce or maintain persistent
immune responses. While live, attenuated and inactivated pathogen
vaccines were effective, in the early days of vaccine manufacturing
there were many issues including contamination, potency and
quality of pathogen production, and lack of standardised
harvesting processes.
At the end of the 19th century, many of the fundamental aspects of
vaccinology were in place because of the pioneering work of
scientists like Pasteur, Koch, Metchnikoff and Ehrlich. The most
important advance was the demonstration that the administration
of pathogens, either attenuated or inactivated, resulted in
Figure 1.7 Typhoid Mary. Mary Mallon (1869e1938), nicknamed ‘Typhoid Mary’,
gained notoriety as history’s most famous chronic carrier of an infection. She was
a cook employed in various homes and institutions, and was known to have been
the cause of 51 cases of typhoid fever, even though she was apparently healthy.
She was conﬁned to a New York hospital for the last 24 years of her life.
Image e believed to be public domain.
How inactivated vaccines
were discovered
Formaldehyde was used in Gaston
Ramon’s laboratory to clean and sterilise
test tubes and glass ﬂasks. One of the
ﬂasks used for toxin preparation was not
thoroughly rinsed and the remaining
formaldehydewas sufﬁcient to inactivate
bacterial toxins (1924). This observation
appears to have originated the use of
formaldehyde inactivation in vaccines.
Typhoid fever vaccine and
the army
Typhoid fever, a disease spread easily
under primitive sanitary conditions and by
chronic carriers (Figure 1.7), was highly
fearedat the beginning of the 19th century
due to its high case-fatality rate of up to
20%. To protect troops against typhoid
fever, themilitary initiated the
development of a whole cell, inactivated
bacterial vaccine. Typhoid vaccination
was ﬁrst tested in 1896 in 2835 volunteers
of the Indian army (Levine, 2008).
Consequently, the army decided to
vaccinate soldiers sent to the Boer War.
The vaccine caused some adverse events
but a committee reviewed the available
data and concluded that the beneﬁts from
prevention of the disease outweighed the
risksfromvaccination; thismaybetheﬁrst
example of anassessment of the risks and
beneﬁts of vaccination.
VACCINE EVOLUTION 11protection against the disease caused by the respective native
pathogen. Developments in pathogen attenuation processes led
to consistent production of attenuated microbes, and many of the
vaccines employed today are still based on these developments.
Figure 1.8 shows the various vaccine technologies developed
over time.
Figure 1.8 Vaccines and technologies. Vaccine development timeline from the ﬁrst practice of variolation. Most of the technologies are still used
for the development of vaccines. Plasma-derived vaccines have not been used in most countries since the 1990s.
IPV, inactivated polio vaccine; OPV, oral polio vaccine; HPV, human papillomavirus.
12 UNDERSTANDING MODERN VACCINESTOXINS, TOXOIDS AND IMMUNOTHERAPY
At the end of the 19th century, Émile Roux and Alexandre Yersin
discovered that diphtheria and tetanus bacilli produce soluble
molecules called exotoxins, which caused the symptoms of these
infections. Soon after this discovery, Emil von Behring and
Figure 1.9 Tetanus case. Neonatal tetanus is still a risk in
the developing world.
Centers for Disease Control and Prevention.
Key principles of the immune
response were elucidated
in the late 19th century
Host cells that ingest and destroy
invading microbes were identiﬁed by Élie
Metchnikoff and named ‘phagocytes’
(literally ‘eating cells’ from the Greek).
Understanding the way in which hosts
and pathogens interact began to unravel
some of the mysteries of infection and
disease. This led to the concept of
‘natural immunity’ to infection, which
was indispensable for vaccine design.
In 1908, Metchnikoff was awarded the
Nobel Prize in Medicine jointly with Paul
Ehrlich for their work on the theory
of immunity.
VACCINE EVOLUTION 13Shibasaburo Kitasato postulated the serum antitoxin concept. The
use of the term ‘immunisation’ dates from this work, referring to the
rabbit serum that contained the antitoxin as immune serum.
In 1924, Gaston Ramon, a veterinarian at the Pasteur Institute,
applied chemical inactivation to bacterial toxins to produce toxoids
of diphtheria and tetanus. By this method, he transformed the
tetanus toxin with formaldehyde and heat into a safer, non-toxic
product, without changing its immunogenic potential. He called
this chemically treated product ‘anatoxin’ (ie toxoid). This discovery
was also applicable to the toxin produced by the diphtheria bacillus.
The diphtheria toxoid produced by this method was used in
a vaccination programme to greatly minimise fatal cases of
diphtheria in infants. The tetanus toxoid vaccine was widely used to
prevent tetanus from battle wounds sustained during World War II.
The introduction of tetanus vaccination has almost eliminated the
number of cases in developed countries; however, tetanus remains
a problem, largely in the developing world (Figure 1.9). Worldwide
annual deaths in 2004 from tetanus were estimated to be 163,000,
144,000 of which occured in children less than 5 years of age
(WHO, 2009).
Another major contribution to the development of vaccines in the
early 1920s came with the discovery that certain substances could
increase yields of immune sera containing antitoxins. The research
carried out by Alexander Glenny and Gaston Ramon was primarily
intended to increase the yields of hyperimmune sera produced in
animals such as horses, rather than to increase the active immune
response after antigenic stimulation in humans. Ramon noted that
horses that spontaneously developed abscesses at the injection
site produced greater serum antitoxin titres. Subsequently, he
successfully described a group of substances, ranging from starch,
bread crumbs and tapioca (used because they contained starch),
which, when injected in conjunction with toxoids, enhanced the
immune response. These substances were tested because it was
already known that they caused aseptic abscesses/inﬂammation.
The term adjuvants, from the Latin adjuvare (‘to help or to aid’), was
coined by Ramon to describe these substances. Around the same
First Nobel Prize in Medicine
The discovery of antibodies in 1890 and
passive immunotherapy of diphtheria
was honoured in 1901 when the ﬁrst
Nobel Prize in Medicine was awarded to
Emil von Behring.
The burden of diphtheria
before the availability
of vaccines
From 1920 to 1940, between 40,000 and
70,000 cases of diphtheriawere recorded
each year in the UK, but by the 1990s the
number was around 10 cases a year.
14 UNDERSTANDING MODERN VACCINEStime, aluminium salts were tested by Glenny (1926) to increase the
immune response to the diphtheria toxoid in horses and, shortly
after, in humans. Today, 80 years later, aluminium salts still remain
the most commonly used adjuvant in vaccines (see Chapter 4 e
Vaccine adjuvants).EMBRYONATED EGGS
In 1931, Ernest Goodpasture introduced the use of embryonated
hen’s eggs as a medium for growing viruses. This technique
represented a major advance since, until its introduction, human
viruses could only be grown in animals such as ferrets and mice.
The chick embryo proved to be a cheaper and safer medium for
the culture of viruses. Using the egg system, Max Theiler at The
Rockefeller Foundation developed an effective vaccine for yellow
fever in the 1930s and received the Nobel Prize in Medicine in
1951. Vaccines against typhus that were important for troops in
World War II were also developed during the 1930s. The ﬁrst
inﬂuenza vaccine was developed in 1940, and was a live, attenuated
virus produced in hen’s eggs. However, due to the instability of the
viral genome, the viruses mutated rapidly and were not attenuated
consistently, causing outbreaks of disease in vaccinees, which led
to the discontinuation of the product for safety reasons.THE CELL CULTURE ERA
In 1906, Albert Calmette and Albert Guérin started to culture
Mycobacterium bovis bacillus in a potato medium to which glycerin
and beef bile were added to strip the lipids from the waxy capsule of
the microorganism. After 13 years and 230 passages through the
medium, they obtained an attenuated strain, bacillus Calmettee
Guérin (BCG). The ﬁrst BCG vaccine became available in 1927 and
is still widely used for the prevention of disseminated TB and TB
meningitis in children.
During the 1930s, the use of animal cell cultures to grow
pathogens became available. This important new technology for
Discovery of viruses as
infectious agents
In 1884, the ChamberlandePasteur ﬁlter
was invented. It had pores smaller than
bacteria, so it was possible to completely
removebacteria through theﬁlter. In1892,
a new class of non-ﬁlterable infectious
agentswasdiscovered: theviruses.Due to
their small size, viruses were not visible
using conventional microscopes, and it
was not until 1931, with the application of
an electron microscope, that the ﬁrst
images of viruses were obtained.
In the early 20th century, the differences
VACCINE EVOLUTION 15the development of vaccines replaced the practice of deliberate
animal-to-animal transmission of infection.
The ﬁrst virus grown in a chicken kidney cell culture was the vaccinia
(cowpox) virus. Following these ﬁrst experiences with animal cell
cultures, viruses were cultivated in human cells, either directly in
primary cell cultures or in immortalised (continuously growing) cell
lines. Vaccine development shifted into a higher gear after 1949
when John Enders, Thomas Weller and Frederick Robbins
demonstrated the ability of poliomyelitis viruses to grow in cultures
of various types of tissue. For making this fundamental discovery
these three scientists were honoured with the Nobel Prize in
Medicine in 1954. This technology provided a relatively easy and
safe way to grow viruses in monolayer cell cultures and paved the
way to a polio vaccine.between viruses and bacteria began to
emerge. The main obstacle encountered
in studying viruses was the fact that they
only multiply within living cells.THE POLIO EXPERIENCE
In the 1950s and early 1960s there was intensive research to develop
safe and effective polio vaccines. Jonas Salk focused on the
development of a formaldehyde inactivated polio vaccine (IPV) with
a virus grown in cell culture systems. The testing of the trivalent IPV
began in 1952, results of the ﬁeld trial were reported in 1955, and the
vaccine was licensed in the USA in the same year. However, in 1955,
during a rush to develop sufﬁcient vaccine for widespread use,
manufacturing failures resulted in inadequate formalin inactivation of
the virus, causing many cases of active disease and death (a
disaster now known as the ‘Cutter incident’). As a result of this
tragedy more rigorous safety testing for vaccines was implemented.
In parallel with the IPV development, Albert Sabin was working on
a live, attenuated poliovirus vaccine (oral polio vaccine, OPV), which
was licensed in the USA in 1963 and replaced IPV in many countries
due to ease of oral administration, efﬁcacy in inducing herd
immunity and lower cost. Until the 1990s, OPV was the primary
vaccine recommended in the USA and most of Europe. However,
with the disappearance of polio in these and other regions,
concerns about the rare occurrence of reversion to virulence and
Figure 1.10 Child with polio. Polio has been eradicated in most countries of the
world; however, outbreaks still occur in developing countries.
Karen Kasmauski/Science Faction/Getty Images.
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WHO polio position paper
“Prior to polio eradication, national
immunisation schedules should include
either oral polio vaccine, inactivated polio
vaccine, or a combination of both. Vaccine
decisions should be based on
assessments of the potential for
importation of wild poliovirus (WPV) and
subsequent transmission. High
immunisation coverage is essential to
ensure adequate population immunity. As
long as WPV transmission has not been
interrupted everywhere, all polio-free
countries and areas remain at risk of
re-importation, particularly from the
remaining polio-endemic countries.”
Source: WHO (2010)
VACCINE EVOLUTION 17release of live virulent vaccine-strain virus into the environment led
to the reassessment of the OPV beneﬁterisk proﬁle. This resulted in
the introduction of a new high-potency IPV in many countries where
polio has already been eliminated. In developing countries,
however, OPV remains the ﬁrst-choice vaccine due to its lower cost,
high efﬁcacy and ease of administration (Figure 1.10).
Polio immunisation opened the door to other live, attenuated virus
vaccines, such as those against measles, mumps, rubella and
varicella. In the 1970s, a combined measles-mumps-rubella (MMR)
vaccine was developed to minimise the total number of injections
in infants. Data from clinical trials with MMR demonstrated that
a combination of antigens could be administered safely
and effectively.
Despite many signiﬁcant advances, the attenuation of pathogens
was still based largely on empirical observations of virulence.
A more targeted attenuation would not become possible until
advances in molecular biology allowed virulence determinants to be
speciﬁcally targeted for deletion or disruption.The need for new technologies
to develop new vaccines
When developing new vaccines, the most
directapproach (which ingeneral involves
the whole pathogen) will be used
unless there are overriding safety,
immunogenicity or practical reasons that
make this impossible. In such instances,
alternative strategies are employed, such
as puriﬁed, recombinant or conjugated
antigens in conjunction with adjuvants, or
the use of novel delivery systems.FROM WHOLE CELLS TO SPLIT AND SUBUNIT VACCINES
Whole organism vaccines for pathogens, such as inﬂuenza or
pertussis, presented barriers to acceptance due to their
reactogenicity proﬁle, eg up to 20% of vaccinees receiving the
original form of whole inactivated inﬂuenza vaccine developed fever
and malaise. The pertussis vaccine caused high rates of fever
and was alleged to cause some cases of encephalitis in children.
This was subsequently shown to be unsubstantiated, but there
was a loss of public conﬁdence and reduced vaccination coverage.
These safety concerns prompted research on other approaches
to the production of safer and more effective vaccines.
Vaccine technology in the late 20th century evolved from growing
and producing pathogens on a large scale in cell culture to deﬁning
and selecting protective antigens. Antigen puriﬁcation was
historically initiated with the manufacture of split inﬂuenza vaccines,
18 UNDERSTANDING MODERN VACCINESwhereby the inﬂuenza vaccine was treated with a solvent to dissolve
or disrupt the viral lipid envelope. In the 1970s, the ﬁrst split
inﬂuenza vaccines were produced using these fragmentation and
puriﬁcation techniques.
Further progress in biotechnology has allowed components of
pathogens to be isolated and produced in large quantities. This
was an extension of the toxoid approach, which many years earlier
showed that it was unnecessary to include the whole organism in
some vaccines. By eliminating any unwanted pathogenic
components like lipids and nucleoproteins, the high purity of these
antigens resulted in vaccines with reduced reactogenicity and
improved safety proﬁles. The subunit approach utilises selected
and puriﬁed single proteins or antigens, such as pertussis
proteins, which form the acellular vaccine, or pneumococcal
polysaccharides. In general, split and subunit vaccines are less
reactogenic compared with the whole pathogen but, in many
instances, they also have reduced immunogenicity.
In the early 1980s, the recombinant protein concept, built on
advances in genetic engineering from the 1970s onwards, enabled
a further technological leap in vaccine development. In this
technique, a section of DNA coding for an antigenic protein is
inserted into an expression system and the protein encoded is
produced in large quantities. The recombinant proteins are
harvested and puriﬁed from the expression system for incorporation
into the vaccine. The recombinant approach excels at achieving
non-infectious, highly pure antigen; in addition, it allows the
production of antigens in large quantities so providing more doses.The DNA recombinant approach
The ﬁrst hepatitis B virus (HBV) vaccine was developed in 1970 by
a 3-fold inactivation of HBV in plasma from the blood of chronic HBV
carriers (see Chapter 3 e Vaccine antigens). Particles of hepatitis B
surface antigen found in their plasma were immunogenic and
protective as a vaccine and did not cause infection. The ﬁrst
plasma-derived HBV vaccine was manufactured in 1981 with a very
VACCINE EVOLUTION 19good safety record, but despite extensive puriﬁcation measures to
inactivate any potential contaminating agents, physicians and the
general public were very reluctant to use a product that carried even
a remote theoretical risk of contamination with blood-borne agents.
Moreover, as the vaccine depended on human serum from chronic
carriers, sources of antigen were limited. These obstacles
prompted the formulation of the ﬁrst recombinant vaccine; an HBV
vaccine that was as effective as the plasma-derived vaccine was
licensed in 1986. This used the puriﬁed recombinant HBV surface
antigen produced in a yeast expression system.
Since 2006, two additional recombinant vaccines have been made
available. These prevent infection with human papillomavirus (HPV)
types that cause cervical cancer (HPV-16, HPV-18), and one of the
vaccines also prevents infection with HPV types causing genital warts
(HPV-6, HPV-11). The vaccines consist of immunogenic virus-like
particles (VLPs) prepared from recombinant HPV L1 coat protein in
yeast, or insect cells. The coat proteins self-assemble during the
puriﬁcation process and mimic the overall structure of virus particles,
but contain noHPVnucleic acid and cannot cause infection.However,
as with all subunit vaccines and highly puriﬁed antigens obtained with
peptide and recombinant technologies, HPV VLP vaccines require an
adjuvant to enhance their ability to stimulate the immune system.From polysaccharides to
polysaccharide-conjugated vaccines
PNEUMOCOCCAL AND MENINGOCOCCAL VACCINES
A whole inactivated Pneumococcus vaccine was developed in
1911, long before the importance of type-speciﬁc immunity was
known. It is now understood that the serotypic variations in
Pneumococci make developing an effective vaccine extremely
challenging (see Chapter 2e Vaccine immunology and Chapter 3e
Vaccine antigens). In the late 1940s, a multivalent (4e6 types)
capsular polysaccharide vaccine was developed; however, this was
not used extensively as antibiotic therapy for pneumococcal
infections became widely available at the same time.
20 UNDERSTANDING MODERN VACCINESDuring the 1970s and 1980s, several polyvalent bacterial vaccines
consisting of puriﬁed capsular polysaccharides were developed as
even though antibiotics were available, pneumococcal infections
remained common and severe. Meningococcal polysaccharide
group A and C vaccines were launched at the same time.
However, polysaccharide vaccines did not provide an adequate
stimulus to the immature immune systems of children younger
than 2 years of age, and older children and adults required
revaccination every 3e5 years because of the limited duration
of immunity. The preparation of vaccines by conjugation
of polysaccharides to a protein carrier, typically tetanus or
diphtheria toxoid, was introduced to overcome poor
immunogenicity. The ﬁrst 7-valent conjugated pneumococcus
vaccine was developed in the 1990s followed in the 2000s by
two formulations containing additional serotypes. Several group
C meningococcal conjugates with either diphtheria or tetanus
toxoid were developed in the 1990s. A-, C-, W- and Y-type
polysaccharide-conjugated vaccines were then licensed in 2005.
These provide a longer duration of immunity than the
unconjugated polysaccharide vaccines, establish adequate
immune memory and provide immune protection to those
younger than 2 years of age.
HAEMOPHILUS INFLUENZA VACCINES
In 1892, Haemophilus inﬂuenzae type b (Hib), the most common
cause of invasive bacterial disease, was isolated. In the 1930s,
the role of the Hib polysaccharide capsule as a virulence factor in
the disease was identiﬁed. The ﬁrst attempts to develop an Hib
vaccine started in the 1970s and a vaccine was licensed in 1985.
As with other polysaccharide vaccines, this vaccine had limited
immunogenicity and was not effective in children younger than 18
months. The ﬁrst conjugated Hib vaccine, licensed in 1987, had
excellent efﬁcacy and immunogenicity, even in infants. Several
Hib vaccines were licensed in the early 1990s and their
widespread use has eliminated much of the Hib disease in
Western countries.
VACCINE EVOLUTION 21The improved pneumococcal, meningococcal and Hib-conjugated
vaccines have led to massive reductions in cases of invasive
disease in children and adolescents, and reductions in the overall
number of cases in the whole population due to the beneﬁts of
herd immunity.From live attenuated to
reassortant viruses
New vaccine technologies appeared in the 1990s, including
reassortment and cold adaptation, which made it possible to
develop successful live, attenuated inﬂuenza vaccines.
Understanding of the molecular mechanisms involved in viralTABLE 1.2. IMPACT OF VACCINES IN THE USA
Disease
Pre-vaccination e estimated annual average Post-vaccination (year)
Cases Deaths Cases Deaths
Diphtheria 21,053 1822 0 (2006) 0 (2004)
Measles 530,217 440 55 (2006) 0 (2004)
Mumps 162,344 39 6584 (2006) 0 (2004)
Pertussis 200,752 4034 15,632 (2006) 27 (2004)
Poliomyelitis, acute 19,794 1393 0 (2006) 0 (2004)
Poliomyelitis, paralytic 16,316 1879 0 (2006) 0 (2004)
Rubella 47,745 17 11 (2006) 0 (2004)
Congenital rubella syndrome 152 Not available 1 (2006) 0 (2004)
Smallpox 29,005 337 0 (2006) 0 (2004)
Tetanus 580 472 41 (2006) 4 (2004)
Hepatitis A 117,333 137 3579 (2006) 18 (2006)
Acute hepatitis B 66,232 237 4713 (2006) 47 (2006)
Invasive Hib 20,000 1000 208 (2006) <5 (2006)
Invasive pneumococcal disease 63,067 6500 5169 (2006) 4850 (2006)
Varicella 4,085,120 105 48,445 (2006) 19 (2006)
Adapted from Roush and Murphy (2007).
Hib, Haemophilus inﬂuenzae type b.
Adherence to vaccination
programmes is of the utmost
importance for the control
or eradication of
infectious diseases
There are several examples, such as the
outbreak of pertussis in Japan in 1975
and ofmeasles in theUK in 2006, showing
how diseases once close to eradication
in particular regions can re-emerge
because vaccination coverage declines
below a critical threshold.
Following initiation of widespread
vaccination of children in the late 1950s,
diphtheria was well-controlled and
outbreaks were uncommon in the Soviet
Union for more than two decades. After
the break-up of the Soviet Union, there
was a collapse of the public health
infrastructure including vaccination
programmes. In 1990, a massive
diphtheria epidemic was observed in the
successor states, resulting in more than
4000 deaths (CDC, 1996).
In Nigeria in the 1990s, a rumour that the
polio vaccine caused sterility resulted in
large portions of the population refusing
to be vaccinated. Thismisinformation and
vaccination breakdown resulted in the
2009 polio outbreak in Nigeria and polio is
currently spreading to neighbouring
countries. Similarly, Tajikistan, which had
beenpolio-free since 1996,was reinfected
with poliovirus from northern India in
2010. By mid-May 2010, paralysis was
reported in more than 430 children (WHO,
2010). TheWHO notes that events such as
these indicate a threat to the goal of
a polio-free world.
22 UNDERSTANDING MODERN VACCINESattenuation led to the development of reassortant technology
(see Chapter 3 e Vaccine antigens). Co-infection of cell culture
with wild and attenuated strains allows the viruses to ‘swap’
genome segments, producing new variants with desirable
genetic components selectively derived from multiple strains. This
technique is possible in viruses, such as the rotavirus, where the
genome of the organism is arranged in physically separate RNA
segments. Co-infection of cell cultures with different strains results
in viruses containing genetic material from all strains. A pentavalent
rotavirus vaccine licensed in 2006 is based on an attenuated bovine
rotavirus reassorted with human rotavirus segments.Conclusion
Vaccination programmes have helped to signiﬁcantly reduce the
number of reported cases of diseases worldwide (Table 1.2
summarises the impact of vaccines in the USA). Successful
eradication of diseases can be achieved through vaccination of
pathogens that have no human reservoir, are non-variable and
have solid immunity/no latency. Smallpox is the ﬁrst success
story and eradication of polio is a distinct possibility having
already been eradicated from many regions of the world. For
many other diseases that meet these criteria, eradication is on
the horizon with the ongoing development of many new vaccines
(see Chapter 6 e Vaccines of the future).
The majority of vaccines being developed today use technologies
based on a better understanding of immune responses, the ability to
generate the antigen on a mass scale and our increased knowledge
of hostepathogen interactions. At present, the focus is on subunit
(puriﬁed protein or polysaccharide), genetically engineered and
vectored antigens (see Chapter 3 e Vaccine antigens). Most
recently, the key role played by antigen-presenting cells in the
connection between the innate and adaptive immune systems has
been recognised. The discovery of the immunological interplay
between immune cells of these systems has opened new doors in
vaccine design (see Chapter 2 e Vaccine immunology).
VACCINE EVOLUTION 23Knowledge of how pathogens evoke the defensive triggers of the
immune system, together with a better understanding of how
immune cells subsequently react and develop an immune
response, has prompted much research in improving the visibility of
the antigen to the innate immune system. Among other areas of
ongoing research (see Chapter 6 e Vaccines of the future), the use
of adjuvants is seen today as one of the most promising and
advanced approaches in guiding the immune system to an
appropriate immune response to the vaccine antigen (see Chapter
4 e Vaccine adjuvants).
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